耐多药革兰氏阴性菌所致肺炎的当前治疗趋势
Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria.
作者信息
Watkins Richard R, Van Duin David
机构信息
Division of Infectious Diseases, Cleveland Clinic Akron General, Akron, OH, 44302, USA.
Department of Medicine, Northeast Ohio Medical University, Rootstown, OH, 44272, USA.
出版信息
F1000Res. 2019 Jan 30;8. doi: 10.12688/f1000research.16517.2. eCollection 2019.
Pneumonia is one of the most common infections worldwide. Morbidity, mortality, and healthcare costs increase substantially when pneumonia is caused by multidrug-resistant Gram-negative bacteria (MDR-GNB). The ongoing spread of antimicrobial resistance has made treating MDR-GNB pneumonia increasingly difficult. Fortunately, there have been some recent additions to our antibiotic armamentarium in the US and Europe for MDR-GNB, along with several agents that are in advanced stages of development. In this article, we review the risk factors for and current management of MDR-GNB pneumonia as well as novel agents with activity against these important and challenging pathogens.
肺炎是全球最常见的感染之一。当肺炎由多重耐药革兰氏阴性菌（MDR-GNB）引起时，发病率、死亡率和医疗成本会大幅上升。抗菌药物耐药性的不断传播使得治疗MDR-GNB肺炎变得越来越困难。幸运的是，美国和欧洲最近在治疗MDR-GNB的抗生素储备中增加了一些药物，还有几种药物正处于研发后期。在本文中，我们回顾了MDR-GNB肺炎的危险因素、当前的治疗方法以及对这些重要且具有挑战性的病原体有活性的新型药物。
Zotero 插件